Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578502 | 0.97 | CA1 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL31388915 | 0.97 | CA1 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL23340283 | 0.92 | CA1 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2875483 | 0.88 | CA2 (0.48) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL352595 | 0.86 | CA1 (0.44) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL36242 | 0.85 | CA2 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL21522547 | 0.82 | CA2 (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL3168827 | 0.82 | CA2 (0.50) | CA1CA2MMP1MMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL21384843 | 0.82 | CA2 (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL21522549 | 0.82 | CA2 (0.50) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794583-A | Bisbenzimidazole STING agonist immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-3081564-B1 | INDOLE DERIVATIVES AS LABELING DYE FOR BIOMOLECULE | PIERCE BIOTECHNOLOGY INC (US) | 2019-07-10 | — | — | EP | claimed |
| EP-2686680-B1 | FLUORESCENT DYES, FLUORESCENT DYE KITS, AND METHODS OF PREPARING LABELED MOLECULES | BIOTIUM INC (US) | 2018-06-13 | — | — | EP | claimed |
| US-9814759-B2 | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | CHEER GLOBAL LTD. (HK) | 2017-11-14 | — | — | US | claimed |
| US-9732101-B2 | Bioreversible boronates for delivery of molecules into cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-08-15 | — | — | US | claimed |
| EP-3001813-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN- BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | Vision Global Holdings Ltd. (CN) | 2016-04-06 | — | — | EP | claimed |
| US-20160024122-A1 | BIOREVERSIBLE BORONATES FOR DELIVERY OF MOLECULES INTO CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | claimed |
| US-20160000864-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RECOMBINANT HEMOGLOBIN PROTEIN OR SUBUNIT-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT | CHEER GLOBAL LTD. (HK) | 2016-01-07 | — | — | US | claimed |
| WO-2014186301-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN- BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | VISION GLOBAL HOLDINGS LTD. (CN) | 2014-11-20 | — | — | WO | claimed |
| US-20140335018-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING | VISION GLOBAL HOLDINGS LTD. (HK) | 2014-11-13 | — | — | US | claimed |
| EP-1792949-A2 | Hydrophilic marker on the basis of diastereomeric cyanines | Dyomics GmbH (DE) | 2007-06-06 | — | — | EP | claimed |
| US-20060239922-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE HEALTHCARE UK LIMITED (GB) | 2006-10-26 | — | — | US | claimed |
| WO-2006111726-A1 | WATER SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE HEALTHCARE UK LIMITED (GB) | 2006-10-26 | — | — | WO | claimed |
| US-20060057573-A1 | Methods and reagents for detecting target binding by nucleic acid ligands | SOMALOGIC, INC (US) | 2006-03-16 | — | — | US | claimed |
| US-20050085622-A1 | Method for modifying protein or peptide C-terminal | SHIMADZU CORPORATION (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1481090-A1 | METHODS AND REAGENTS FOR DETECTING TARGET BINDING BY NUCLEIC ACID LIGANDS | SomaLogic, Inc. (US) | 2004-12-01 | — | — | EP | claimed |
| EP-1476753-A2 | FUNCTIONALIZED COMPOSITIONS FOR IMPROVED IMMOBILIZATION | Luminex Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| US-20040039201-A1 | Functionalized compositions for improved immobilization | LUMINEX CORPORATION | 2004-02-26 | — | — | US | claimed |
| WO-2003084982-A2 | FUNCTIONALIZED COMPOSITIONS FOR IMPROVED IMMOBILIZATION | LUMINEX CORPORATION (US) | 2003-10-16 | — | — | WO | claimed |
| WO-2003070984-A1 | METHODS AND REAGENTS FOR DETECTING TARGET BINDING BY NUCLEIC ACID LIGANDS | SOMALOGIC, INC. (US) | 2003-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060239922-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | TPD52L2, MRPL21, MRPL9 | CA1 1035/4885CA2 1581/4885MMP1 2866/4885 |
| US-20160024122-A1 | BIOREVERSIBLE BORONATES FOR DELIVERY OF MOLECULES INTO CELLS | BAG6, BCAP31, PHB1 | CA1 2615/4885CA2 853/4885MMP1 3916/4885 |
| US-20050085622-A1 | Method for modifying protein or peptide C-terminal | PTMS, DNPEP, PTMA | CA1 960/4885CA2 3851/4885MMP1 2940/4885 |
| US-20040039201-A1 | Functionalized compositions for improved immobilization | ILK, EPCAM, ICAM1 | CA1 431/4885CA2 629/4885MMP1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.